Ticker
SAN
Analysis
Sanofi Sa investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to SAN.
Sanofi Sa investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to SAN.
SAN
Stock
$101.33B
Health Technology
Pharmaceuticals: Major
EUR
Sanofi Sa may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without
Sanofi’s Cenrifki (tolebrutinib) approved in the EU as the first disability-targeting medicine for secondary progressive multiple sclerosis without relapses Cenrifki represents ...
The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in Abu Dhabi, and Sanofi, a worldwide biopharma and vaccines leader, have signed an Memorandum...
Sanofi appoints Paulo Fontoura as Global Head of
Sanofi’s Sarclisa subcutaneous formulation approved in Japan for patients with multiple
Review valuation context for Sanofi Sa.
Review future growth context for Sanofi Sa.
Review past performance context for Sanofi Sa.
Review financial health context for Sanofi Sa.
Review dividend context for Sanofi Sa.
Review management context for Sanofi Sa.
Review ownership context for Sanofi Sa.
Review other information context for Sanofi Sa.
Review community context for Sanofi Sa.